Stryker (NYSE:SYK) said today that paid $52 million (£35.6 million) in cash for SIW Holdings subsidiary Stanmore Implants, which makes medical devices for limb salvage in patients with orthopedic cancers. “The acquisition of Stanmore Implants provides Stryker with differentiated technologies designed to provide the most effective solutions for orthopedic oncology surgeons. This addition underscores Stryker’s commitment […]
The FDA slapped Stanmore Implants with an import ban until the British orthopedic implant maker deals with problems flagged in a warning letter from the federal safety watchdog.
U.K.-based orthopedic device maker Stanmore Implants says it has received FDA clearance for its Sculptor Robotic Guidance Arm system for partial knee resurfacing procedures.
The system uses a robotic guidance arm to assist surgeons’ operation of cutting tools, and "limiting the removal of bone to a pre-defined safe area," according to a prepared release. It is part of a suite of devices and software systems the company produces for personalized orthopedic implants.
Burlington, Mass.-based ConforMIS filed documents officially contesting a patent application for a personalized knee replacement system that Stanmore Implants claims to be the world’s 1st.
Boston Scientific Corp. (NYSE:BSX) lauded a new guidance released by the research arm of the U.K.’s National Health Service, the country’s publicly funded health care system.
The National Institute for Health & Clinical Excellence issued a final guidance for bronchial thermoplasty as an option for patients with severe asthma that isn’t controllable with drugs, a boon for Boston Scientific’s Alair.
Smith & Nephew (NYSE:SNN) won a nod from the FDA for its Pico negative-pressure wound therapy system.
The British orthopedics giant’s wound care division said the FDA cleared the device for use in the home and in hospitals. It’s already on the market in Europe, Canada and Australia, according to a press release.
Cardiac medical device firm Sunshine Heart (ASX:SHC) raised $4.6 million by selling 115 million shares in a private placement with institutional investors in the U.S. and Canada at 4 cents per share.
The Eden Prairie, Minnesota-based company is developing the C-Pulse(R) Heart Assist System, an implantable, non-blood-contacting, heart assist therapy to treat moderate to severe heart failure.
Stanmore Implants won FDA clearance for an extendible femur implant that can "grow" as the patient does, without the need for surgery, anesthesia or sedation.
The Juvenile Tumour System replaces large portions of the femoral bone in the thigh, which is sometimes removed during cancer treatment.